Altered BDNF Methylation in Patients with Chronic Musculoskeletal Pain and High Biopsychosocial Complexity
Open Access
- 1 June 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Journal of Pain Research
- Vol. ume 13, 1289-1296
- https://doi.org/10.2147/jpr.s251782
Abstract
Purpose: The INTERMED instrument, which was developed to measure patient’s biopsychosocial (BPS) complexity, represents a powerful diagnostic and therapeutic tool. Epigenetic changes are the interface between signals from the environment and genetic modifications, affecting gene expression, in particular, by DNA methylation of CpG dinucleotides in promotor regions of the corresponding genes. The brain-derived neurotrophic factor (BDNF) gene plays a crucial role in the central sensitization (CS) of pain. In this study, we hypothesized that chronic pain modifies the methylation levels of the BDNF gene in a manner that is interconnected with the BPS status. Patients and Methods: Fifty-eight chronic musculoskeletal pain patients (CMSP) were enrolled in the study. DNA was extracted from blood samples, the methylation levels of 13 CpG sites in the BDNF promoter were measured by pyrosequencing, and association studies with various patient parameters and the INTERMED scores were performed. Results: Interestingly, a negative correlation (− 0.40) was found between the total INTERMED scores and the average CpG methylation values of the BDNF gene, but no correlation was observed with the severity of pain, degree of anxiety, depression, or kinesiophobia and catastrophism. Moreover, the association was independent of age, sex and level of comorbidities. Conclusion: This result shows that CMSP, in association with its biopsychosocial context, epigenetically decreases the degree of methylation of the BDNF promoter and should therefore increase the level of BDNF transcription. It also suggests a role of the INTERMED tool to detect a relationship between the BPS complexity and the epigenetic control of a target gene. The possible upregulation of BDNF expression might be, at least in part, the signal for chronic pain-induced central sensitization (CS). This could partly explain why patients with a higher level of complexity feel more pain than those with lower complexity.Keywords
This publication has 43 references indexed in Scilit:
- Central sensitization: Implications for the diagnosis and treatment of painPain, 2011
- Rehabilitation outcomes for orthopaedic trauma individuals as measured by the INTERMEDDisability and Rehabilitation, 2011
- Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4)Pain, 2005
- The INTERMED: a screening instrument to identify multiple sclerosis patients in need of multidisciplinary treatmentJournal of Neurology, Neurosurgery & Psychiatry, 2003
- DNA methylation patterns and epigenetic memoryGenes & Development, 2002
- “INTERMED”: a method to assess health service needs: I. Development and reliabilityGeneral Hospital Psychiatry, 1999
- INTERMED-An Assessment and Classification System for Case ComplexitySpine, 1999
- The Pain Catastrophizing Scale: Development and validation.Psychological Assessment, 1995
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983
- The Need for a New Medical Model: A Challenge for BiomedicineScience, 1977